Survival
Prognostic Significance of B7-H3 Expression and CD163+ Tumor-Associated Macrophage Infiltration in Mesothelioma
International Journal of Molecular Sciences 2026 August 3 [Link] Tülay Koç, Ramazan Oğuz Yüceer, Tuncay Altay, Neslihan Taş, Serkan Çelikgün Abstract Mesothelioma is a rare, aggressive malignancy with poor prognosis. B7-H3 (CD276), an immune checkpoint molecule, and CD163-positive tumor-associated macrophages (TAMs) contribute to tumor progression and immune evasion. This study evaluated the prognostic impact of…
Read MoreInsights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines
Thoracic Cancer 2026 August [Link] Yani Wu, Fang Cao, Jiayin Dai, Zhenli Yang, Yanli Zhu, Dongmei Lin, Xiaocui Bian, Yuqin Liu Abstract Background: Pleural mesothelioma (PM) is an aggressive cancer with limited therapeutic options and poor prognosis, necessitating comprehensive model systems for mechanistic studies and drug discovery. Methods: Tumor cells were isolated from malignant pleural…
Read MoreLow baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma
Lung Cancer 2026 September [Link] Antoine Torchiat, Karina Silina, Arya Ashok Nair, Laura Viktoria Heeb, Isabelle Opitz, Anurag Gupta, Alessandra Curioni-Fontecedro Abstract Introduction: The cyclic GMP-AMP synthase (cGAS)/STING pathway, a central DNA-sensing mechanism, is known to activate anti-tumor immune response but may also promote tumor progression when chronically activated. Given the role of asbestos-induced chronic…
Read MoreEfficacy of Perioperative Platinum-Pemetrexed Chemotherapy Combined With Pleurectomy/Decortication for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July 25 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Kyoshiro Takegahara, Takashi Kijima, Seiki Hasegawa, Soichiro Funaki Abstract Background: The optimal timing of chemotherapy in multimodal treatment of pleural mesothelioma remains unclear. This study evaluated the efficacy of adjuvant chemotherapy (AC) after neoadjuvant chemotherapy (NAC)…
Read MoreThe Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
Clinical Medicine Insights Oncology 2026 July 24 [Link] Jiaojiao Hong, Xianzi Dai, Jiangxia Yuan, Chengyu Chen, Zhengxing Huo, Chunwei Xu, Qian Wang Abstract Background: Malignant pleural mesothelioma (MPM) originates from pleural mesothelial cells and represents a highly aggressive malignancy. Characterized by a prolonged latency period, poor survival prognosis, and non-specific clinical manifestations, MPM poses significant…
Read MoreEpiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma
Lung Cancer 2026 September [Link] Roberta Noberini, Ioanna Bischinioti, Simone Zanetti, Alessandro Vai, Giulia Sedda, Eltjona Mane, Claudia Bardoni, Giulia Robusti, Marianna D’Ercole, Rosanna Mancari, Ugo Cavallaro, Nicoletta Colombo, Luca Bertolaccini, Mariano Lombardi, Nicola Fusco, Lorenzo Spaggiari, Domenico Galetta, Tiziana Bonaldi Abstract Pleural mesothelioma (PM) is an aggressive tumor that arises from mesothelial cells as…
Read MoreTreatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication
Annals of Surgical Oncology 2026 October [Link] Ryo Wakejima, Hironori Ishibashi, Ayaka Asakawa, Yuya Ishikawa, Yusuke Sugita, Kenichi Okubo Abstract Background: We evaluate recurrence patterns and assess the efficacy of local treatment for oligo-recurrence in patients with diffuse pleural mesothelioma (PM) following extended pleurectomy/decortication (P/D) with multimodal therapy. Methods: This retrospective study included 69 patients…
Read MoreMaintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
Scientific Reports 2026 July 15 [Link] Okan Aydin, Zehra Sucuoglu Isleyen, Mert Erciyestepe, Ahmet Emin Ozturk, Sermin Dinc Sonusen, Tugay Atasever, Simay Cokgezer, Ebru Cicek, Ayse Gul Satman Durmaz, Lamia Seker Can, Gozde Balkaya Aykut, Tuba Baydas, Miray Aydogan, Seval Ay Ersoy, Muhammed Mustafa Atci, Kayhan Erturk Abstract Malignant pleural mesothelioma (MPM) is an aggressive…
Read MoreNavigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Cancers 2026 June 30 [Link] Giorgio D’Annibale, Francesco Santullo, Lorenzo Barberis, Claudio Lodoli, Tommaso Partipilo, Giusi Giulia La Manna, Antonia Strippoli, Alexia Spring, Fabio Pacelli, Carlo Abatini Abstract Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing…
Read MorePrognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
NPJ Precision Oncology 2026 July 9 [Link] Justin M Bader, Ankit Dhiman, Nicole Aguirre, Kwasi Ansere Ofori, Princy Gupta, Hannah Qin, Anup Sharma, Owen Mitchell, Melissa Y Tjota, Aliya N Husain, Michael Drazer, Jane Churpek, Hedy Kindler, Kiran Turaga Abstract Mesothelioma is a rare cancer with poor prognosis. Somatic mutations show prognostic value in smaller…
Read More